{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-014768","form_type":"8-K","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2022-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.561669+00:00","generated_at":"2026-06-26T07:14:19.201012+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Brooklyn ImmunoTherapeutics reports FY2021 net loss of $122.3M; cash $17M","bullets":["Net loss $122.3M for FY2021 vs $26.5M in 2020; Q4 loss $8.5M vs $21.5M.","Operating expenses $113.6M, including $80.5M acquired IPR&D from Novellus deal.","Cash $17.0M at Dec 31, 2021, up from $1.6M a year ago; raised $52M via equity sales.","Completed Novellus acquisition in July 2021; new executives appointed.","Phase 2b head & neck cancer trial readout for IRX-2 expected Q2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-014768","json":"https://secwatch.observer/filing/0001140361-22-014768.json","markdown":"https://secwatch.observer/filing/0001140361-22-014768.md","text":"https://secwatch.observer/filing/0001140361-22-014768.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000114036122014768/0001140361-22-014768-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000114036122014768/brhc10036443_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T07:14:19.201012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}